Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
9.85
+0.07 (0.72%)
At close: Dec 5, 2025, 4:00 PM EST
9.89
+0.04 (0.41%)
After-hours: Dec 5, 2025, 7:34 PM EST
Telix Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Telix Pharmaceuticals stock have an average target of 21, with a low estimate of 20 and a high estimate of 22. The average target predicts an increase of 113.20% from the current stock price of 9.85.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 23, 2025.
Analyst Ratings
The average analyst rating for Telix Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $23 → $20 | Strong Buy | Maintains | $23 → $20 | +103.05% | Sep 23, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $22 | Strong Buy | Initiates | $22 | +123.35% | Sep 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $23 → $20 | Strong Buy | Maintains | $23 → $20 | +103.05% | Sep 10, 2025 |
| Wedbush | Wedbush | Buy Reiterates $22 | Buy | Reiterates | $22 | +123.35% | Aug 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +133.50% | Jul 3, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.